The IDHmut glioma patients with low MPS1 mRNA expression had a significantly longer survival (LogRank: p = 0.02, Cox regression: p = 0.06, Hazard-Ratio: 8.0 (95% CI: 0.9–66.7) than those with high MPS1 mRNA expression (Figure 3d). This evidence concerns the gene TTK and central nervous system cancer.